Cellestia Biotech: Innovative therapeutics that matter




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Cellestia Biotech: Innovative therapeutics that matter
Released on: October 24, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Cellestia Biotech is a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway.
  • Summary
  • Participants
  • Company
Cellestia Biotech is a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway. Michael Bauer discusses with Fintan Walton
Chief Executive Officer and Board member of Cellestia Biotech AG, Basel, Switzerland. Michael is a senior drug development professional with over 18 years’ experience in the life sciences industry. He served in senior leadership positions across disciplines such as clinical and preclinical drug development, project & portfolio management, regulatory affairs and metabolism research. He has many years of experience in leading global development projects, covering the full range of drug development, from early stage preclinical through Phase I, II and III clinical development, including IND and NDA submissions. Most recent assignments were with Novartis Pharma AG, Translational Medicine Oncology, working as Senior Global Program Manager Development and Polyphor Ltd., where he served as Head of Clinical Development. Under his leadership, several new oncology drugs were brought into clinical development and reached clinical proof of concept. Michael holds a Ph.D. in Biotechnology and M.Sc. in Chemistry.
A Startup with more than 15 years of research in oncology Cellestia’s pipeline is supported by more than 15 years of research in the field of oncology and cancer stem cells biology conducted under the supervision of Prof. Freddy Radtke. Cellestia Biotech AG was founded in 2014 as a spin-off from? Ecole Polytechnique Fédérale de Lausanne, EPFL and is managed by a high-calibre team of academic and industry professionals. Vision of Cellestia Cellestia is actively engaged in the development of first-in-class mechanisms-based targeted therapeutics to address unmet medical needs, with an emphasis on oncology and immunological disorders. Our anti-cancer CB-103 is a novel, first-in-class, oral pan-NOTCH inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.